BioForce Nanosciences Reports Financial Struggles Amid Cash Increase and No Sales Revenue in Q1 2025

BioForce Nanosciences Holdings, Inc. (PINK: BFNH) has released its quarterly report for the period ending March 31, 2025, detailing significant financial challenges while navigating the supplement market.

Positive Aspects:

• Increase in Assets: Cash increased from $862 at the end of December 2024 to $13,799 by March 31, 2025.
• Capital from Related Parties: The company raised $28,152 in financing activities during the quarter from related parties, a slight increase from $17,583 in the same quarter of 2024.
• Expansion of Shares: Issued 4,250,000 shares to settle accrued compensation, enhancing liquidity.

Negative Aspects:

• No Sales Revenue: The company reported $0 in sales for both the current and prior-year quarter, indicating ongoing difficulties in generating revenue.
• Increasing Losses: Net loss surged to $934,650 for Q1 2025 compared to $130,813 in Q1 2024, primarily due to a significant loss on liability settlement of $801,193.
• High Operating Expenses: Total operating expenses of $133,457 increased from $130,813, attributed to rising general and administrative costs.
• Accumulated Deficit: The company now has an accumulated deficit of $162,054,816, exacerbating its financial challenges.
• Working Capital Deficit: Reported at $261,242, raising concerns about the company's ability to meet short-term obligations.
• Going Concern Warnings: The report highlights significant doubts regarding the ability to continue as a going concern given the recurring losses and reliance on loans from officers to fund operations.

Key Statistics:

• Cash and total current assets: $13,799 (up from $862)
• Total liabilities: $275,041 (down from $2,302,454)
• Net cash used in operating activities: $15,215
• Net loss per share: $(0.03)
• Weighted average number of shares: 32,246,755

This report suggests that while BioForce Nanosciences is improving cash resources through capital raising efforts, its inability to generate sales revenue and significant losses raise substantial concerns about its operational viability moving forward.